The efficacy of ibrutinib in the treatment of Richter syndrome

Blood. 2015 Mar 5;125(10):1676-8. doi: 10.1182/blood-2014-12-610782.

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
² Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
³ Department of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ.
⁴ Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
⁵ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Aged
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / therapeutic use
Disease-Free Survival
Doxorubicin / therapeutic use
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male
Middle Aged
Piperidines
Prednisone / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Rituximab
Syndrome
Vincristine / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
R-CHOP protocol
ibrutinib
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Adenine
Prednisone

Grants and funding